Representative Julie Johnson (D-Texas) recently sold shares of Johnson & Johnson NYSE: JNJ. In a filing disclosed on May 14th, the Representative disclosed that they had sold between $1,001 and $15,000 in Johnson & Johnson stock on April 1st. The trade occurred in the Representative's "MERRILL LYNCH TAX EFFICIENT CORE" account.
Representative Julie Johnson also recently made the following trade(s):
- Purchased $1,001 - $15,000 in shares of Fidelity National Information Services NYSE: FIS on 4/30/2025.
- Sold $1,001 - $15,000 in shares of Blackstone NYSE: BX on 4/22/2025.
- Purchased $1,001 - $15,000 in shares of Fidelity National Information Services NYSE: FIS on 4/22/2025.
- Sold $1,001 - $15,000 in shares of United Parcel Service NYSE: UPS on 4/15/2025.
- Sold $1,001 - $15,000 in shares of United Parcel Service NYSE: UPS on 4/11/2025.
- Purchased $1,001 - $15,000 in shares of 3M NYSE: MMM on 4/11/2025.
- Sold $1,001 - $15,000 in shares of DT Midstream NYSE: DTM on 4/7/2025.
- Sold $1,001 - $15,000 in shares of Intuitive Surgical NASDAQ: ISRG on 4/7/2025.
- Sold $1,001 - $15,000 in shares of Howmet Aerospace NYSE: HWM on 4/7/2025.
- Sold $1,001 - $15,000 in shares of Carlisle Companies NYSE: CSL on 4/7/2025.
Johnson & Johnson Stock Performance
JNJ stock traded up $1.09 during mid-day trading on Tuesday, reaching $153.58. The company had a trading volume of 7,344,994 shares, compared to its average volume of 7,966,598. The stock's 50-day simple moving average is $156.06 and its two-hundred day simple moving average is $153.80. The stock has a market capitalization of $369.52 billion, a P/E ratio of 23.09, a P/E/G ratio of 2.56 and a beta of 0.42. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. Research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.
Johnson & Johnson Increases Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a yield of 3.39%. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's payout ratio is currently 57.84%.
Insiders Place Their Bets
In related news, VP Robert J. Decker sold 6,999 shares of the stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the transaction, the vice president now owns 21,001 shares in the company, valued at approximately $3,483,645.88. This represents a 25.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.16% of the company's stock.
Analyst Ratings Changes
A number of equities analysts recently issued reports on the company. Guggenheim reissued a "neutral" rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Bank of America decreased their price target on Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a research note on Thursday, April 10th. Wells Fargo & Company cut their price objective on shares of Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating on the stock in a research note on Thursday, January 23rd. Leerink Partners lowered shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and decreased their target price for the company from $169.00 to $153.00 in a research report on Tuesday, May 13th. Finally, The Goldman Sachs Group upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and boosted their price target for the stock from $157.00 to $172.00 in a research report on Wednesday, April 9th. Eleven equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $170.88.
Read Our Latest Analysis on Johnson & Johnson
Institutional Trading of Johnson & Johnson
A number of large investors have recently added to or reduced their stakes in the business. Acorns Advisers LLC purchased a new stake in Johnson & Johnson during the first quarter valued at about $263,000. Blue Rock Wealth Management LLC grew its position in Johnson & Johnson by 324.5% during the 1st quarter. Blue Rock Wealth Management LLC now owns 6,486 shares of the company's stock worth $1,076,000 after purchasing an additional 4,958 shares in the last quarter. Fortis Capital Advisors LLC lifted its stake in Johnson & Johnson by 411.7% in the 1st quarter. Fortis Capital Advisors LLC now owns 14,962 shares of the company's stock worth $2,481,000 after acquiring an additional 12,038 shares in the last quarter. Belpointe Asset Management LLC boosted its holdings in shares of Johnson & Johnson by 35.7% during the first quarter. Belpointe Asset Management LLC now owns 32,189 shares of the company's stock worth $5,338,000 after purchasing an additional 8,477 shares during the period. Finally, Focus Partners Wealth grew its holdings in shares of Johnson & Johnson by 15.4% during the 1st quarter. Focus Partners Wealth now owns 1,193,378 shares of the company's stock valued at $197,910,000 after acquiring an additional 159,419 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.
About Representative Johnson
Julie Johnson (Democratic Party) is a member of the U.S. House, representing Texas' 32nd Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.
Johnson (Democratic Party) ran for election to the U.S. House to represent Texas' 32nd Congressional District. She won in the general election on November 5, 2024.
Julie Johnson earned a B.A. in history and government from the University of Texas at Austin in 1987 and a J.D. from the University of Houston Law Center in 1991. Johnson's career experience includes working as an attorney.
About Johnson & Johnson
(
Get Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
See Also
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
